Form 8-K - Current report:
SEC Accession No. 0001193125-25-070521
Filing Date
2025-04-01
Accepted
2025-04-01 17:01:35
Documents
13
Period of Report
2025-03-27
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d920617d8k.htm   iXBRL 8-K 31078
  Complete submission text file 0001193125-25-070521.txt   151227

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lyel-20250327.xsd EX-101.SCH 2843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20250327_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20250327_pre.xml EX-101.PRE 10807
15 EXTRACTED XBRL INSTANCE DOCUMENT d920617d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 25800668
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)